{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:02:44Z","timestamp":1720382564537},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.leukres.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T02:39:37Z","timestamp":1518575977000},"page":"67-74","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Recent advances in the genomics and therapy of BCR\/ABL1 -positive and -negative chronic myeloproliferative neoplasms"],"prefix":"10.1016","volume":"67","author":[{"given":"Tariq I.","family":"Mughal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdnan","family":"Verstovek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.02.008_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.02.008_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0020","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood-2017-05-781237","article-title":"A molecular roadmap for midostaurin in mastocytosis","volume":"130","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0025","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.02.008_bib0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2018.02.008_bib0040","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2018.02.008_bib0050","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"2","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0055","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampf","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0065","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the WHO classification in myeloid neoplasms and acute leukemias","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0070","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"2\u20134","key":"10.1016\/j.leukres.2018.02.008_bib0080","doi-asserted-by":"crossref","first-page":"e1248011","DOI":"10.1080\/21623996.2016.1248011","article-title":"Chasing down the triple-negative myeloproliferative neoplasms: implications for molecular diagnostics","volume":"5","author":"Langabeer","year":"2016","journal-title":"JAK-STAT"},{"key":"10.1016\/j.leukres.2018.02.008_bib0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12032-017-0944-z","article-title":"Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms","volume":"34","author":"Chang","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0090","series-title":"Genetic Testing and Molecular Biomarkers","author":"Frawley","year":"2018"},{"key":"10.1016\/j.leukres.2018.02.008_bib0095","first-page":"7","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"66","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0100","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0105","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/leu.2017.161","article-title":"Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia","volume":"31","author":"Heilmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0115","first-page":"4219","article-title":"Comprehensive genetic characterization of 63 myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFR-\u03b1, PDGFR-\u03b2, FGFR1 or PCM1-JAK2","volume":"130","author":"Baer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0120","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.02.008_bib0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0130","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/leu.2015.130","article-title":"Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus","volume":"29","author":"Chase","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0135","article-title":"A case report of chronic myelogenous leukemia with JAK2- and BCR-ABL-positive mutation","author":"Sircilla","year":"2017","journal-title":"AJHO"},{"key":"10.1016\/j.leukres.2018.02.008_bib0140","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0145","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0150","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0155","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0160","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2018.02.008_bib0165","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant Calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.leukres.2018.02.008_bib0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion","volume":"13","author":"Han","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0180","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2016.280","article-title":"A novel signaling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation","volume":"31","author":"Kollmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ajh.24245","article-title":"Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism","volume":"91","author":"Garbati","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0195","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"54","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"issue":"6","key":"10.1016\/j.leukres.2018.02.008_bib0200","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2018.02.008_bib0205","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2018.02.008_bib0210","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.leukres.2018.02.008_bib0215","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification, and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.02.008_bib0220","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.leukres.2018.02.008_bib0225","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2018.02.008_bib0230","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.02.008_bib0235","first-page":"17","article-title":"PKC412 \u2014 a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des."},{"issue":"July","key":"10.1016\/j.leukres.2018.02.008_bib0240","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.leukres.2018.02.008_bib0245","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2018.02.008_bib0250","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.leukres.2018.02.008_bib0255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0260","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1056\/NEJMe1700833","article-title":"Imatinib changed everything","volume":"376","author":"Longo","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.02.008_bib0265","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/cam4.801","article-title":"Deep molecular responses for treatment-free remission in chronic myeloid leukemia","volume":"5","author":"Dulucq","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2018.02.008_bib0270","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0275","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0280","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0285","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of cessation for chronic myeloid leukemia patients with stable undetected minimal residual disease \u2013results from TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.008_bib0290","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0295","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"issue":"July (7)","key":"10.1016\/j.leukres.2018.02.008_bib0300","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0305","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0310","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.008_bib0315","series-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, v1.2018-July 26","author":"National Comprehensive Cancer Network","year":"2017"},{"issue":"21","key":"10.1016\/j.leukres.2018.02.008_bib0320","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V122.21.4042.4042","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0330","first-page":"238","article-title":"Factors that influence patient willingness to attempt treatment-free remission in chronic myeloid leukemia","volume":"101","author":"Ross","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2018.02.008_bib0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0340","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1080\/10428194.2017.1330476","article-title":"Are chronic myeloid leukemia patients ready to stop long-term treatment?","volume":"58","author":"Breccia","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"May","key":"10.1016\/j.leukres.2018.02.008_bib0345","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY); an interim analysis of a non-randomised, phase 2 trial","author":"Clark","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.02.008_bib0350","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2018.02.008_bib0355","first-page":"787","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.02.008_bib0360","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0365","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3118.3118","article-title":"Clinical outcomes with ruxolitinib (RUX) in patients with myelofibrosis (MF) stratified by transfusion status: a pooled analysis of the COMFORT-I and -II trials","volume":"128","author":"Gupta","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.008_bib0370","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0375","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3110.3110","article-title":"A pooled overall survival (OS) analysis of 5-year data from the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF)","volume":"128","author":"Verstovsek","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1949.1949","article-title":"Effects of long-term ruxolitinib (RUX) on bone marrow (BM) morphology in patients with myelofibrosis (MF) enrolled in the COMFORT-I study","volume":"128","author":"Kvasnicka","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0385","first-page":"1","article-title":"Myeloproliferayive neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"1","author":"Koschmeider","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.008_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myeofibrosis irrespective of baseline cytopenias (PERSIST-1): an international randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0395","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1123.1123","article-title":"Momelotinib therapy in myelofibrosis: 6-years follow-up data on safety, efficacy and the impact of mutations on overall and relapse-free survival","volume":"128","author":"Tefferi","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.008_bib0400","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trail","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0405","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5","article-title":"Results of the persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts <100,000\/\u03bcl","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0410","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.4418","article-title":"Phase 3 trail of momelotinib (MMB) vs ruxoltinib (RUX) in JAK inhibitor (JAKi) na#xp#ve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0415","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1936.1936","article-title":"Phase 1\/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (postPV MF), or post-essential thrombocythemia myelofibrosis (postET MF)","volume":"128","author":"Verstovsek","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.02.008_bib0420","first-page":"1058","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"100","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.leukres.2018.02.008_bib0425","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2018.02.008_bib0430","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0435","article-title":"Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0440","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1124.1124","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in patients with blast-phase MPN and post-MPN AML: results of a phase I study (myeloproliferative disorders research consortium 109 trial)","volume":"128","author":"Rampal","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0445","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1125.1125","article-title":"Preliminary results from a phase I dose escalation trial of ruxolitinib and the PI3K\u03b4 inhibitor TGR-1202 in myelofibrosis","volume":"128","author":"Moyo","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2018.02.008_bib0450","article-title":"PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks","volume":"126","author":"Verstovek","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0455","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.478.478","article-title":"Phase-2 study of sotatercept (ACE-011) in myeloproliferative neoplasm-associated myelofibrosis and anemia","volume":"128","author":"Bose","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0460","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.479.479","article-title":"Interim analysis of the myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0465","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4271.4271","volume":"128","author":"Mesa","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.02.008_bib0470","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.475.475","article-title":"Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients","volume":"128","author":"Gisslinger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.008_bib0475","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-assocaited cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2018.02.008_bib0480","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2018.02.008_bib0485","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrsoine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systemic review and meta-analysis","volume":"2","author":"Douxfils","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0490","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00277-017-3012-z","article-title":"Evaluation of cardiovascular ishaemic evnts rates in dasatinib-treted patients using standarize incidence ratios","volume":"96","author":"Saglio","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0495","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System","volume":"90","author":"Cortes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.008_bib0500","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeoid leukemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2018.02.008_bib0505","doi-asserted-by":"crossref","first-page":"e18550","DOI":"10.1200\/JCO.2017.35.15_suppl.e18550","article-title":"The effect of aspirin and anticoagulation on tyrosine kinase inhibitors induceed thrombotic events in chronic myeloid leukemia: a retrospective cohort","volume":"35","author":"Numan","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:09:47Z","timestamp":1603843787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618300432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":101,"alternative-id":["S0145212618300432"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the genomics and therapy of BCR\/ABL1-positive and -negative chronic myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}